© 2018 LabShares Newton LLC

abcuro logo.jpeg


Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both autoimmunity and cancer.


They leverage the systematic target validation and clinical insights gained by its founders to identify new targets.

Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivo validation in diseased tissue has uncovered new approaches to target key compartments of the immune system.